Mylan's life-saving EpiPen injection device is not the only medication in the company's portfolio that has seen large price spikes, reports NBC News.
In June, Wells Fargo Senior Analyst David Maris wrote a report that investigated Mylan's pricing practices and predicted the scrutiny that currently surrounds the Amsterdam-based drugmaker.
"Mylan has raised the prices more than 20 percent on 24 products, and more than 100 percent on seven products," said Mr. Maris.
Here are four drugs produced by Mylan that have seen huge price hikes this year.
- Ursodiol, a generic medication used to treat gallstones, saw a 542 percent increase.
- The generic drug metoclopramide,intended to treat gastroesophageal reflux disease, increased by 444 percent.
- Dicyclomine, used to treat irritable bowel syndrome, rose in price by 400 percent.
- Mylan's best-selling overactive bladder treatment tolterodine increased by 56 percent.
"Mylan's business model is not today, nor has it ever been, premised on price hikes," said Mylan spokeswoman Nina Devlin in an email to Bloomberg. "A flawed analysis focusing on a small number of products out of the more than 1,400 products Mylan sells globally and the approximately 600 products we sell in North America is simply self-serving and misleading to investors."
More articles on drug costs:
Sen. Bernie Sanders urges Pfizer to lower cost of Xtandi following Medivation acquisition
4 ways the FDA is contributing to high generic drug costs
As CEO of Mylan, Senator's daughter faces brunt of EpiPen backlash